What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

Biomarker

PUBLISHER: 360iResearch | PRODUCT CODE: 2171008

PUBLISHER: 360iResearch | PRODUCT CODE: 2171008

Predictive Biomarkers Market - Global Forecast 2026-2032

PUBLISHED: November 2, 2026

PAGES: 193 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The Predictive Biomarkers Market is projected to grow by USD 82.74 billion at a CAGR of 17.61% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 26.57 billion
Estimated Year [2026]	USD 30.89 billion
Forecast Year [2032]	USD 82.74 billion
CAGR (%)	17.61%

Predictive Biomarkers: Introduction and Strategic Significance

Predictive biomarkers are measurable biological characteristics used to anticipate how a patient is likely to respond to a specific therapy. They support treatment selection, clinical-trial enrichment, companion-diagnostic development, and more individualized care across oncology, immunology, infectious disease, and other therapeutic areas. Their value depends on analytical validity, clinical validity, clinical utility, reproducibility, and integration into real-world workflows.

Transformative Shifts Reshaping Predictive Biomarker Development

The field is shifting from single-analyte testing toward multimodal approaches that combine genomic, transcriptomic, proteomic, pathological, and clinical information. Broader sequencing access, digital pathology, liquid-biopsy research, and decentralized sample collection are expanding the range of measurable signals. At the same time, regulators, payers, laboratories, and healthcare providers are placing greater emphasis on evidence quality, test standardization, interoperability, turnaround time, and equitable access.

How Artificial Intelligence Is Changing Predictive Biomarker Workflows

Artificial intelligence is being applied to identify candidate biomarkers, interpret complex molecular profiles, analyze medical images, stratify trial participants, and support treatment-response prediction. Its practical contribution is strongest when models are trained on representative, well-annotated data and validated across institutions and patient populations. Key safeguards include transparent performance reporting, bias assessment, human oversight, data governance, cybersecurity, and prospective evaluation before routine clinical use.

Regional Insights Across Predictive Biomarker Ecosystems

North America benefits from advanced translational research, established molecular-testing infrastructure, and active links between drug development and diagnostics. Europe emphasizes coordinated evidence generation, data protection, laboratory quality, and cross-border regulatory alignment. Asia-Pacific combines strong research capacity in several markets with substantial variation in laboratory access, reimbursement, and clinical standardization. Latin America is expanding precision-medicine capabilities while continuing to address infrastructure, affordability, and workforce constraints. The Middle East is investing in genomics, specialized healthcare, and national data programs, whereas Africa presents significant unmet need alongside emerging genomic initiatives and uneven access to validated testing.

Group Insights: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN markets show diverse levels of molecular-testing maturity, creating opportunities for shared standards, regional referral networks, and workforce development. BRICS economies combine major patient populations and research capabilities with differences in regulatory systems, funding, and access. The European Union benefits from coordinated scientific and regulatory frameworks, although implementation remains heterogeneous across member states. G7 countries generally have mature clinical-research ecosystems and stronger laboratory infrastructure, while still confronting cost, interoperability, and population-representation challenges. GCC countries are strengthening precision-health capacity through centralized investment and specialized care. NATO members vary widely in healthcare organization but share interest in resilient biomedical supply chains, secure health data, and advanced research collaboration.

Country Insights: Market Readiness and Evidence Priorities

The United States and Canada have broad translational research and testing capabilities, with continued focus on reimbursement, evidence standards, and access disparities. The United Kingdom, France, Germany, Italy, and Spain are advancing precision medicine within structured public-health systems, while addressing differing adoption pathways and laboratory coordination. China, Japan, South Korea, India, and Australia combine sophisticated research activity with varying population diversity, regulatory processes, and access across urban and rural settings. Brazil, Mexico, and Russia are developing capabilities amid differences in healthcare financing, infrastructure, and availability of specialized testing. Across all countries, priorities include locally representative validation, standardized preanalytics, clinician education, and integration of results into treatment pathways.

Actionable Priorities for Predictive Biomarker Leaders

Leaders should define the clinical decision a biomarker is intended to improve before selecting technologies or endpoints. They should build evidence plans spanning analytical validation, clinical performance, utility, health-economic value, and post-deployment monitoring. Interoperable data architectures, quality-controlled laboratory networks, and partnerships among clinicians, diagnostic specialists, researchers, regulators, and patient groups can improve implementation. Organizations should also use diverse datasets, document model limitations, protect sensitive information, and design access strategies that account for geography, affordability, and health-system capacity.

Research Methodology for the Executive Summary

This summary uses a structured qualitative assessment of predictive-biomarker development and adoption, organized by technology, clinical workflow, evidence requirements, geography, and stakeholder group. Insights are grounded in established principles of biomarker validation, precision medicine, clinical diagnostics, artificial-intelligence governance, and healthcare implementation. Regional, group, and country comparisons are presented as contextual observations rather than quantitative rankings or market measurements. No market estimates, shares, forecasts, or company-specific claims are used.

Conclusion: Building Reliable and Equitable Predictive Biomarker Systems

Predictive biomarkers can make treatment selection more precise, improve trial design, and support more efficient use of healthcare resources when supported by rigorous evidence and dependable implementation. The next phase will depend less on discovery alone and more on reproducibility, multimodal validation, responsible artificial intelligence, interoperable infrastructure, and equitable access. Industry leaders that connect scientific innovation with clinical utility and trustworthy governance will be best positioned to translate biomarker insights into meaningful patient outcomes.

Product Code: MRR-8639DE1748F2

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Predictive Biomarkers Market, by Biomarker Type

7.1. Introduction
7.2. Genomic Biomarkers
- 7.2.1. DNA Mutations
- 7.2.2. Copy Number Alterations
- 7.2.3. Gene Rearrangements
7.3. Immunological Biomarkers
7.4. Proteomic Biomarkers
- 7.4.1. Protein Expression
- 7.4.2. Phosphoproteins
7.5. Epigenetic Biomarkers
7.6. Transcriptomic Biomarkers
- 7.6.1. mRNA Expression
- 7.6.2. microRNA
7.7. Metabolomic Biomarkers
- 7.7.1. Lipid Metabolites
- 7.7.2. Amino Acid Metabolites

8. Predictive Biomarkers Market, by Product

8.1. Introduction
8.2. Consumables
- 8.2.1. Assay Kits
- 8.2.2. Detection Kits
- 8.2.3. Reagents
8.3. Services
- 8.3.1. Biomarker Discovery
- 8.3.2. Biomarker Validation
- 8.3.3. Clinical Biomarker Testing
- 8.3.4. Assay Development
8.4. Instruments
- 8.4.1. Sequencing Systems
- 8.4.2. PCR Systems
- 8.4.3. Mass Spectrometry Systems
- 8.4.4. Immunoassay Analyzers
- 8.4.5. Imaging Systems
- 8.4.6. Flow Cytometry Systems
- 8.4.7. Microarray Systems
8.5. Software
- 8.5.1. Bioinformatics Platforms
- 8.5.2. AI Analytics

9. Predictive Biomarkers Market, by Analytical Technology

9.1. Introduction
9.2. Immunoassays
9.3. Next-Generation Sequencing
9.4. Polymerase Chain Reaction
9.5. Mass Spectrometry
9.6. Immunohistochemistry
9.7. Flow Cytometry
9.8. Microarray Analysis
9.9. Fluorescence In Situ Hybridization
9.10. CRISPR-based Diagnostic Platforms

10. Predictive Biomarkers Market, by Therapeutic Area

10.1. Introduction
10.2. Oncology
- 10.2.1. Lung Cancer
- 10.2.2. Breast Cancer
- 10.2.3. Colorectal Cancer
- 10.2.4. Prostate Cancer
- 10.2.5. Lymphoid Malignancies
- 10.2.6. Myeloid Malignancies
- 10.2.7. Melanoma
- 10.2.8. Ovarian Cancer
- 10.2.9. Pancreatic Cancer
10.3. Cardiovascular Diseases
10.4. Neurological Disorders
- 10.4.1. Alzheimer's Disease
- 10.4.2. Parkinson's Disease
10.5. Metabolic Disorders
- 10.5.1. Diabetes
- 10.5.2. Obesity
10.6. Autoimmune Diseases
10.7. Infectious Diseases
- 10.7.1. HIV
- 10.7.2. Hepatitis
10.8. Respiratory Diseases
10.9. Renal Diseases

11. Predictive Biomarkers Market, by Assay Configuration

11.1. Introduction
11.2. Multi-Biomarker Panels
11.3. Single-Biomarker Assays

12. Predictive Biomarkers Market, by Application

12.1. Introduction
12.2. Drug Development
12.3. Clinical Decision Support
12.4. Precision Medicine
12.5. Disease Risk Prediction
12.6. Pharmacogenomics

13. Predictive Biomarkers Market, by End User

13.1. Introduction
13.2. Pharmaceutical Companies
13.3. Clinical Laboratories
13.4. Biotechnology Companies
13.5. Academic and Research Institutions
13.6. Diagnostic Laboratories
13.7. Hospitals
13.8. Contract Research Organizations

14. Predictive Biomarkers Market, by Region

14.1. Introduction
14.2. North America
14.3. Europe
14.4. Asia-Pacific
14.5. Latin America
14.6. Middle East
14.7. Africa

15. Predictive Biomarkers Market, by Group

15.1. Introduction
15.2. NATO
15.3. G7
15.4. European Union
15.5. BRICS
15.6. ASEAN
15.7. GCC

16. Predictive Biomarkers Market, by Country

16.1. Introduction
16.2. United States
16.3. China
16.4. Germany
16.5. Japan
16.6. France
16.7. Italy
16.8. Canada
16.9. United Kingdom
16.10. Spain
16.11. India
16.12. Brazil
16.13. South Korea
16.14. Australia
16.15. Russia
16.16. Mexico

17. Competitive Landscape

17.1. Market Share Analysis, 2025
17.2. Market Concentration Analysis, 2025
- 17.2.1. Concentration Ratio (CR)
- 17.2.2. Herfindahl Hirschman Index (HHI)
17.3. Recent Developments & Impact Analysis, 2025
17.4. Product Portfolio Analysis, 2025
17.5. Benchmarking Analysis, 2025

18. Company Profiles

18.1. F. Hoffmann-La Roche Ltd
18.2. Thermo Fisher Scientific Inc.
18.3. Danaher Corporation
18.4. Tempus AI, Inc.
18.5. Labcorp Holdings Inc.
18.6. QIAGEN N.V.
18.7. Illumina, Inc.
18.8. Guardant Health, Inc.
18.9. Revvity, Inc.
18.10. Myriad Genetics, Inc.
18.11. Caris Life Sciences, Inc.
18.12. NeoGenomics, Inc.
18.13. Quest Diagnostics Incorporated
18.14. Natera, Inc.
18.15. Eurofins Scientific SE
18.16. Agilent Technologies, Inc.
18.17. IQVIA Holdings Inc.
18.18. Bio-Rad Laboratories, Inc.
18.19. Veracyte, Inc.
18.20. Oxford BioDynamics Plc
18.21. 10x Genomics, Inc.
18.22. Abbott Molecular, Inc.
18.23. Axe Compute Inc.
18.24. Biodesix, Inc.
18.25. bioMerieux Inc.
18.26. BostonGene Corporation
18.27. Bruker Corporation
18.28. Charles River Laboratories International, Inc.
18.29. Crown Bioscience, Inc.
18.30. MDxHealth SA
18.31. Metabolon, Inc.
18.32. OncoDNA SA
18.33. Owkin, Inc.
18.34. PathAI, Inc.
18.35. Personalis, Inc.
18.36. Quanterix Corporation
18.37. Standard BioTools Inc.
18.38. Sysmex Corporation

19. Key Experts